Boston Scientific Corporation $BSX Shares Bought by Louisbourg Investments Inc.

Louisbourg Investments Inc. boosted its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 968.9% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 84,087 shares of the medical equipment provider’s stock after purchasing an additional 76,220 shares during the period. Louisbourg Investments Inc.’s holdings in Boston Scientific were worth $5,276,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the stock. Renaissance Group LLC purchased a new position in shares of Boston Scientific in the fourth quarter worth about $28,064,000. Rathbones Group PLC boosted its position in Boston Scientific by 20.9% in the fourth quarter. Rathbones Group PLC now owns 2,759,657 shares of the medical equipment provider’s stock valued at $263,133,000 after buying an additional 477,680 shares during the last quarter. Tounjian Advisory Partners LLC purchased a new stake in Boston Scientific in the fourth quarter valued at approximately $1,477,000. Waycross Partners LLC acquired a new position in Boston Scientific in the 4th quarter worth approximately $2,384,000. Finally, Kepler Cheuvreux Suisse SA acquired a new position in Boston Scientific in the 3rd quarter worth approximately $26,955,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Activity at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig acquired 3,580 shares of the company’s stock in a transaction on Wednesday, May 20th. The shares were bought at an average cost of $56.68 per share, with a total value of $202,914.40. Following the completion of the acquisition, the director owned 25,359 shares in the company, valued at approximately $1,437,348.12. This trade represents a 16.44% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director David C. Habiger acquired 2,250 shares of the business’s stock in a transaction dated Wednesday, May 20th. The stock was acquired at an average price of $55.92 per share, with a total value of $125,820.00. Following the completion of the transaction, the director directly owned 13,878 shares of the company’s stock, valued at approximately $776,057.76. This represents a 19.35% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders acquired a total of 9,800 shares of company stock worth $554,012 in the last 90 days. Corporate insiders own 0.34% of the company’s stock.

Wall Street Analysts Forecast Growth

BSX has been the subject of several research reports. Robert W. Baird set a $70.00 price objective on shares of Boston Scientific in a research note on Thursday, May 28th. Weiss Ratings cut shares of Boston Scientific from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, May 13th. Stifel Nicolaus decreased their target price on shares of Boston Scientific from $75.00 to $65.00 and set a “buy” rating for the company in a research report on Thursday. Jefferies Financial Group cut their price target on Boston Scientific from $100.00 to $67.00 and set a “buy” rating on the stock in a research report on Wednesday. Finally, Zacks Research lowered Boston Scientific from a “hold” rating to a “strong sell” rating in a research note on Friday, June 5th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $83.36.

Boston Scientific Price Performance

Shares of NYSE BSX opened at $44.16 on Friday. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. The stock has a market capitalization of $65.64 billion, a price-to-earnings ratio of 18.48, a PEG ratio of 0.85 and a beta of 0.56. The firm’s 50 day simple moving average is $52.87 and its 200-day simple moving average is $71.13. Boston Scientific Corporation has a 12 month low of $43.89 and a 12 month high of $109.50.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. The firm had revenue of $5.20 billion for the quarter, compared to the consensus estimate of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The firm’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Analysts expect that Boston Scientific Corporation will post 3.36 EPS for the current year.

Boston Scientific declared that its Board of Directors has initiated a share repurchase plan on Monday, May 18th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s board of directors believes its stock is undervalued.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.